Express Pharma
Home  »  Latest Updates  »  Clinical trials for new diabetes drugs urgently needed In India: ISCR

Clinical trials for new diabetes drugs urgently needed In India: ISCR

12

On the occasion of World Diabetes Day (November 14), the Indian Society for Clinical  Research (ISCR), an association of clinical research professionals, has highlighted the need to adopt better diabetes management practices and develop more efficacious treatment for diabetes and its resultant complications

There is also an urgent need for investments in more clinical research to ensure that patients can benefit from newer and better medicines, says an ISCR release.

This year’s theme ‘Healthy Living and Diabetes’ is particularly pertinent to India which has the second highest number of people with diabetes in the world1 with 66.84 million diabetes cases in the country today, according to 2013 statistics provided by the International Diabetes Federation. An estimated 1 in 12 adults suffer from this lifestyle disease and many cases remain undiagnosed. The ever-increasing diabetes burden has a cascading impact on the nation’s health expenditure and healthcare resources.

Dr Manoj Chawla, Consultant Diabetologist and Coordinator, Department of Diabetology, (Asian Heart institute & Research Centre) an investigator in a recently concluded diabetes clinical trial said, “Given the growing burden of diabetes in our country, it is extremely important for us to test the efficacy of new medicines on our population which is only possible through clinical research. It is not just patients but we, as investigators, as well who benefit from clinical research because through participating in research, we learn more about newly developed drugs, their benefits and risks. This enables us to play a strong role as global opinion leaders in the safety and efficacy of new drugs for native populations,” he added.

 A patient in Delhi who participated in a diabetes trial (name withheld to protect patient confidentiality) said, “I was advised to enrol in clinical research by my diabetologist. Being diagnosed with diabetes, I went through a very difficult time and it was tough on my family too. When I was told about the potential benefits of a new diabetes drug which was not available in the market, I decided to participate in a clinical trial and do not regret it.” He further said, “It felt good to be surrounded by people who, just like me are fighting this lifelong disease. The trial helped me understand my condition better and the medication I received helped me manage my diabetes more efficiently.”

 “The last two years has seen a drop in clinical research being done in the country which has meant delayed access to newer therapies and treatment for our population,” said Suneela Thatte, President, ISCR. “Given that India has the largest disease burden in the world, we hope that the recently amended clinical research regulatory guidelines will see more organisations investing in doing clinical research in the country. We have a moral responsibility to ensure that patients in our country have access to newer and better medicines. Given the high incidence of diabetes in India, clinical research will also help identify which medicines work best for our genetic disposition which is critical to managing our growing diabetes burden.”

EP News Bureau

Comments are closed.